Commerce Dashboard

Lupin Pharmaceuticals

Go Back

Lupin Pharmaceuticals

  • Amongst the top 10 generic companies in the world
  • 18 manufacturing sites
  • Products sold in more than 100 countries
  • Its consolidated income stood at Rs 15,858.5 crore (US$ 2.25 billion) in FY20

Lupin Ltd. is a leading pharmaceutical company from India and is amongst the top 10 generic companies in the world. It started its business in 1968 and over the years has become one of the largest pharmaceutical companies in India and the world. Its businesses include formulations, Active Pharmaceutical Ingredients (API), drug delivery systems and biotechnology. In FY20, Lupin’s total sales stood at Rs. 15,142.8 crore (US$ 1.72 billion).

Company Website:

2021 In June 2021, the company’s board of directors approved a proposal to enter the digital healthcare space in India. It incorporated Lupin Digital Health Ltd., a wholly owned subsidiary, to provide a digital therapeutics platform for medical practitioners and patients in the country.
In May 2021, Lupin entered a royalty-free, non-exclusive licensing agreement with Eli Lilly and Company for expanding access to the COVID-19 drug, Baricitinib. The company will now manufacture and distribute the drug in India.
In March 2021, Lupin and, an automation start-up, joined forces to expand Lupin’s automation initiatives.

Lupin launched ‘Tacrolimus’ capsules USP, 0.5 mg, 1 mg, and 5 mg, after its partner, Concord Biotech Limited (Concord), received an approval for ANDA (Abbreviated New Drug Application) from the United States Food and Drug Administration 

Lupin launched Favipiravir under the drug name ‘Covihalt’ for the treatment of patients with mild to moderate Covid-19 symptoms. This medicine is available at Rs. 49 (US$ 0.66)/ tablet in India. 

Lupin launched the generic version of Bausch Health's Apriso, used in the treatment of ulcerative colitis, in the US market
2019 Lupin launched Adhero, a first-of-its-kind connected Smart Device in India to support treatment of Respiratory Disease
Received approval for its propranolol Hydrochloride Extended-Release (ER) capsules from Health Canada
Lupin’s subsidiary in South Africa declared commercial agreement with Creso Pharma
Nagpur facility won ENR Global Best Project Award
Launched Doxercalciferol Injection, 4 mcg/2 ml multidose vials, for the treatments of secondary hyperparathyroidism in adult patients with CKD on dialysis
2017 Entered over the counter (OTC) market with launch of Softovac in India
2016 Acquired US-based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc.
2010 Became fifth largest generic player in the US
2004 Commenced US Brands Business with the launch of Suprax
2002 More than 100 patent filings
1993 Lupin Laboratories Ltd. and Lupin Chemicals Ltd. raise money through IPOs
1989 Joint venture in Thailand and Lupin Chemicals (Thailand) Ltd was formed
1980 Commissioned first Formulations plant and an R&D center at Aurangabad, Maharashtra
1968 Commenced business


India ranks 3rd worldwide for pharmaceutical production by volume and 14th by value. The country has an established domestic pharmaceutical industry, with a strong network of 3,000 drug companies and ~10,500 manufacturing units.